TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.
Shanghai Junshi Biosciences Co., Ltd. announced that its subsidiary, Shanghai JunTop Biosciences Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for its JT118 injection. This investigational new drug is a recombinant protein vaccine aimed at preventing monkeypox virus infection, marking a significant step as no such vaccine is currently approved in China. The vaccine has shown promising results in preclinical studies, demonstrating significant protection and a favorable safety profile. This development could enhance the company’s position in the pharmaceutical industry, particularly in the field of infectious disease prevention.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a pharmaceutical company based in China, focusing on the development and commercialization of innovative drugs, particularly in the field of biosciences. The company is involved in creating vaccines and therapeutic solutions, with a market focus on addressing unmet medical needs.
Average Trading Volume: 13,805,868
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.72B
Learn more about 1877 stock on TipRanks’ Stock Analysis page.